Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03165526 · ClinicalTrials.gov registry record

The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study

A clinical trial, sponsored by Abbott Medical Devices.

Completed
Registry status
131
Enrollment target

NCT03165526 is a clinical trial that has completed, run by Abbott Medical Devices. The registered enrollment target is 131 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03165526 has completed, sponsored by Abbott Medical Devices.

COMPLETED
Registry status
131 participants
Enrollment target

Study Summary

FDA issued a Humanitarian Device Exemption (HDE) approval order for the AMPLATZER™ PIVSD Occluder (H070005) on January 10, 2017. The Conditions of Approval require that SJM conduct a post approval study to evaluate the safety and probable benefit of the AMPLATZER™ PIVSD Occluder.

Interventions

  • DEVICE AMPLATZER™ Post-infarct Muscular VSD Occluder

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2018-10-01
Est. Completion 2021-11-29

Sponsor

Abbott Medical Devices

261 total trials

What the Registry Record Tells You About NCT03165526

The ClinicalTrials.gov registry entry for NCT03165526 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which AMPLATZER™ Post-infarct Muscular VSD Occluder is the first listed.

NCT03165526 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03165526 about?

NCT03165526 is a clinical study titled "The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study". FDA issued a Humanitarian Device Exemption (HDE) approval order for the AMPLATZER™ PIVSD Occluder (H070005) on January 10, 2017. The Conditions of Approval require that SJM conduct a post approval study to evaluate the safety and probable benefit of the AMPLATZER™ PIVSD Occluder.

What is the current status of trial NCT03165526?

This trial is currently completed. The enrollment target is 131 participants. The study started on 2018-10-01. Estimated completion is 2021-11-29.

What interventions are being tested in trial NCT03165526?

The interventions under investigation include: AMPLATZER™ Post-infarct Muscular VSD Occluder (DEVICE).

Who is sponsoring clinical trial NCT03165526?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.